More tools:Markets·Screener·Research Chat

Pfizer Inc. (PFE) Financial Statements

Pfizer Inc.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S5V466
XNYS · usd
24.25▼ 0.23 (-0.94%)
As of 2026-07-14
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA—
Financial Highlights
Revenue (TTM)$63.3B
Net Income (TTM)$7.5B
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close24.48
Day's Range24.14 – 24.43
52-Week Range23.11 – 29.57
Volume37.38M
Avg Volume45.08M
Share Statistics
Shares Outstanding5.7B
Employees75.0K
ExchangeXNYS
Listed1951-06-22

Key questions about Pfizer Inc. (PFE)

What is Pfizer Inc.'s Market Cap?
Pfizer Inc.'s Market Cap is $138.2B, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s Enterprise Value?
Pfizer Inc.'s Enterprise Value is $203.0B, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s Trailing P/E?
Pfizer Inc.'s Trailing P/E is 18.5×, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s Price / Sales?
Pfizer Inc.'s Price / Sales is 2.2×, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s EV / Revenue?
Pfizer Inc.'s EV / Revenue is 3.2×, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s Revenue (TTM)?
Pfizer Inc.'s Revenue (TTM) is $63.3B, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s Net Income (TTM)?
Pfizer Inc.'s Net Income (TTM) is $7.5B, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s Diluted EPS (TTM)?
Pfizer Inc.'s Diluted EPS (TTM) is 1.31, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s Net Debt?
Pfizer Inc.'s Net Debt is $63.5B, based on as-reported figures from SEC (XBRL) filings.
Loading Income Statement…
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 29, 2026Dec 31, 2025Sep 28, 2025Jun 29, 2025Mar 30, 2025Dec 31, 2024Sep 29, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Oct 1, 2023Jul 2, 2023Apr 2, 2023Dec 31, 2022Oct 2, 2022Jul 3, 2022Apr 3, 2022
Revenues:
Product revenues
Alliance revenues
Royalty revenues
Total revenues
YoY growth+5.4%-1.2%-5.9%+10.3%-7.8%
Costs and expenses:
Cost of sales (a)
Selling, informational and administrative expenses (a)
Research and development expenses (a)
Acquired in-process research and development expenses
Amortization of intangible assets
Restructuring charges and certain acquisition-related costs
Other (income)/deductions––net
Income from continuing operations before provision/(benefit) for taxes on income
Provision/(benefit) for taxes on income
Income from continuing operations
Discontinued operations––net of tax—
Net income before allocation to noncontrolling interests
% of revenue18.7%-9.3%21.3%20.0%21.7%
Less: Net income attributable to noncontrolling interests
Net income attributable to Pfizer Inc. common shareholders
% of revenue18.6%-9.4%21.3%19.9%21.6%
Earnings per common share––basic :
Income from continuing operations attributable to Pfizer Inc. common shareholders—————
Net income attributable to Pfizer Inc. common shareholders
Earnings per common share––diluted :
Income from continuing operations attributable to Pfizer Inc. common shareholders—————
Net income attributable to Pfizer Inc. common shareholders
Weighted-average shares––basic
Weighted-average shares––diluted